A.P. Pharma submits anti-nausea drug for FDA approval

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

APF530 is undergoing regulatory review for a new drug approval for the prevention of chemotherapy-induced nausea and vomiting, according to manufacturer A.P. Pharma. PF530 is a formulation of granisetron, a 5-HT3 antagonist.

APF530 is undergoing regulatory review for a new drug approval for the prevention of chemotherapy-induced nausea and vomiting, according to manufacturer A.P. Pharma. PF530 is a formulation of granisetron, a 5-HT3 antagonist.

The drug is delivered using the company’s Biochronomer system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.

In a phase III, randomized, multicenter trial of 1,395 cancer patients, APF530 was shown to be as effective as palonosetron (Aloxi) for the prevention of acute onset and delayed onset CINV, A.P. Pharma said in a statement.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content